Because of the multi-system nature of the disease, systemic treatments are invariably used to control generalized inflammation. Primary first-line treatment of GVHD is usually with systemic corticosteroids, which typically results in responses in B50% of patients. 3, 4 For those patients who fail to respond there is no standard second-line therapy that has been validated in welldesigned clinical trials. The majority of patients are treated with other systemic immune-suppressive therapies that target T-cell activation pathways or inflammatory cytokine production. 5 Owing to the widespread tissue involvement that is a characteristic of most patients with GVHD, surgery is generally not considered.
In this report, we present a patient who underwent surgical resection for the treatment of refractory GVHD of the colon. A 66-year-old woman was diagnosed with CLL in June 2008 when she presented with asymptomatic lymphadenopathy. A BM biopsy showed diffuse infiltration with small lymphocytes along with deletion 17p
À on cytogenetic exam. Initial treatment consisted of observation only; however, within six months, she developed progressive leukocytosis, anemia and thrombocytopenia. She was treated with five cycles of fludarabine, CY and rituximab (FCR) and achieved a PR. Nine months after initial treatment she again developed leukocytosis and thrombocytopenia. A BM biopsy was repeated, which demonstrated 90% cellularity with CLL involvement and persistence of 17p À cytogenetic abnormality. Additional new cytogenetic findings with deletion 11q and rearrangement of chromosomes 1 and 3 were noted. She was treated with alemtuzumab for 3 months with persistent disease and then received an HLA-matched allogeneic unrelated PBSC transplant in November 2010. A reduced-intensity conditioning regimen consisting of fludarabine 30 mg/m 2 per day for 3 days and TBI 2 Gy was administered before transplantation. GVHD prophylaxis was with tacrolimus and mycophenolate. Fifty-two days after transplantation, she developed a skin rash covering approximately one half of her body surface accompanied by profuse diarrhea. A skin biopsy showed GVHD. The overall clinical grade was grade 4 (skin grade 2 and gut grade 4). She was started on high-dose methylprednisolone (2 mg/kg per day). Her rash quickly resolved with corticosteroid treatment, however, diarrhea persisted. A subsequent biopsy of the colon confirmed a diagnosis of GVHD. She required total parenteral nutrition because of persistent GVHD and developed recurrent vancomycin-resistant enterococcal (VRE) bacteremia. She subsequently received salvage therapy with infliximab and budesonide without response. Therapy with Tocilizumab resulted in a partial response with a decrease in stool volume and reduction in concomitant immune-suppressive therapy. Despite this improvement she continued to be unable to tolerate a normal diet and had recurrent VRE bacteremia with intermittent hematochezia. Repeat colonoscopy revealed the presence of pseudopolyps and hemorrhage within the mucosa. A computed tomography (CT) scan of the abdomen showed that there was segmental thickening of the colon confined to the distal transverse, descending and sigmoid colon, but preservation of the remaining colon and no inflammation detected within the small intestines. Owing to the failure to completely resolve her symptoms and the localized abnormalities noted on CT scan, a surgical consultation was obtained. After much discussion, a decision was made to resect the area of colonic involvement because of concerns that continued immunosuppression was likely to be ineffectual and expose the patient to ongoing risk of opportunistic infections. On day þ 174 after transplant, she underwent a laparoscopic left hemicolectomy with a total of 52.5 cm of colon removed. Gross examination of the surgical sample revealed large areas of completely denuded mucosa with only small islands of normal appearing tissue (Figure 1a) . Pathological examination revealed extensive ulceration of the mucosa with underlying granulation tissue accompanied by extensive hemorrhage (Figure 1b) , but a clear transition zone where mucosa became normal (Figure 1c) . The postoperative course was complicated by ileus, which resolved with conservative measures. Her symptoms rapidly resolved and she was able to eat a normal diet within 11 days after surgery. She was subsequently discharged home 2 weeks after surgery. Three months after discharge, she continues to do well with no recurrence of diarrhea or GVHD. She is currently on tapering doses of steroids and tacrolimus.
There have been a limited number of patients reported in the literature who have undergone surgical therapy for treatment of recalcitrant GVHD. The majority of cases has been performed for intractable bleeding or bowel obstruction symptoms and involved resection of a portion of the small intestines alone or in conjunction with the right side of the colon. 6 --9 In addition, most cases have been in children or young adults. The current case is the first, to our knowledge, to involve a left-sided hemicolectomy in an elderly patient and was done primarily for persistent diarrhea, which was exacerbated by attempts to advance her diet. The localized involvement of the colon noted on CT scan provided evidence that the bulk of the inflammatory process was confined to this region and did not affect the entire gastrointestinal tract. This was subsequently confirmed after surgical resection where pathological examination showed essentially normal appearing mucosa at the surgical margins. Furthermore, the rapid resolution in patient symptoms and cessation of recurrent bacteremic episodes was additional evidence that GVHD was confined to this segment of the colon. Surgery was done laparoscopically, which reduced complications and allowed for more rapid return to functional status and restoration of a normal diet. In summary, this report demonstrates that GVHD in the colon can be a localized process that is amenable to surgical intervention and that elderly patients can tolerate this procedure without complications.
